OptimizeRx Corp. (NASDAQ:OPRX) Sees Large Decline in Short Interest

OptimizeRx Corp. (NASDAQ:OPRX) saw a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 1,398,242 shares, a decrease of 16.4% from the February 12th total of 1,673,046 shares. Approximately 7.9% of the shares of the company are short sold. Based on an average daily volume of 364,058 shares, the days-to-cover ratio is presently 3.8 days. Based on an average daily volume of 364,058 shares, the days-to-cover ratio is presently 3.8 days. Approximately 7.9% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Stephens reduced their price objective on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday, March 6th. Lake Street Capital dropped their target price on OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Roth Mkm reduced their price target on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 6th. Stifel Nicolaus lowered their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.57.

OptimizeRx Stock Performance

OptimizeRx stock traded up $0.17 during mid-day trading on Monday, hitting $6.57. 260,314 shares of the company’s stock traded hands, compared to its average volume of 410,703. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a one year low of $5.54 and a one year high of $22.25. The firm has a 50 day moving average price of $9.93 and a 200 day moving average price of $14.35. The company has a market cap of $123.25 million, a PE ratio of 25.27 and a beta of 1.21.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. On average, equities analysts forecast that OptimizeRx will post -0.33 EPS for the current year.

OptimizeRx declared that its Board of Directors has initiated a share buyback plan on Thursday, March 5th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Institutional Trading of OptimizeRx

A number of institutional investors have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. increased its stake in shares of OptimizeRx by 10.9% during the fourth quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock valued at $249,000 after acquiring an additional 2,000 shares during the period. Parkman Healthcare Partners LLC lifted its position in OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after purchasing an additional 2,188 shares during the period. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares in the last quarter. AQR Capital Management LLC boosted its stake in OptimizeRx by 18.4% during the 4th quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock valued at $178,000 after purchasing an additional 2,256 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in shares of OptimizeRx by 12.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock valued at $305,000 after purchasing an additional 2,708 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.